Status: Recruiting
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Participants needed: 270
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Incendia TherapeuticsUpdated: Feb 23, 2026Locations: 11
Eligibility criteria
Subject must be willing and able to read, understand, and sign an Informed Conse... [+18]
Subject has received prior treatment with systemic agents, including, but not li... [+19]